149 related articles for article (PubMed ID: 33024263)
21. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
[TBL] [Abstract][Full Text] [Related]
22. BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
[TBL] [Abstract][Full Text] [Related]
23. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
Lovly CM; Dahlman KB; Fohn LE; Su Z; Dias-Santagata D; Hicks DJ; Hucks D; Berry E; Terry C; Duke M; Su Y; Sobolik-Delmaire T; Richmond A; Kelley MC; Vnencak-Jones CL; Iafrate AJ; Sosman J; Pao W
PLoS One; 2012; 7(4):e35309. PubMed ID: 22536370
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
25. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
26. BRAF and NRAS mutations in spitzoid melanocytic lesions.
Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
[TBL] [Abstract][Full Text] [Related]
27. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
28. Rapid clinical mutational testing of
Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
[TBL] [Abstract][Full Text] [Related]
29. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.
Pellegrini C; Cardelli L; Padova M; Nardo LD; Ciciarelli V; Rocco T; Cipolloni G; Clementi M; Cortellini A; Ventura A; Leocata P; Fargnoli MC
Acta Derm Venereol; 2020 Jan; 100(1):adv00040. PubMed ID: 31774543
[TBL] [Abstract][Full Text] [Related]
30. BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Meckbach D; Keim U; Richter S; Leiter U; Eigentler TK; Bauer J; Pflugfelder A; Büttner P; Garbe C; Weide B
PLoS One; 2014; 9(2):e89218. PubMed ID: 24586605
[TBL] [Abstract][Full Text] [Related]
31. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A
Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705
[TBL] [Abstract][Full Text] [Related]
32. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.
Chen G; Chakravarti N; Aardalen K; Lazar AJ; Tetzlaff MT; Wubbenhorst B; Kim SB; Kopetz S; Ledoux AA; Gopal YN; Pereira CG; Deng W; Lee JS; Nathanson KL; Aldape KD; Prieto VG; Stuart D; Davies MA
Clin Cancer Res; 2014 Nov; 20(21):5537-46. PubMed ID: 24803579
[TBL] [Abstract][Full Text] [Related]
34. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
Jahn SW; Kashofer K; Halbwedl I; Winter G; El-Shabrawi-Caelen L; Mentzel T; Hoefler G; Liegl-Atzwanger B
Mod Pathol; 2015 Jul; 28(7):895-903. PubMed ID: 25769001
[TBL] [Abstract][Full Text] [Related]
35. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
36. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Patel SP; Lazar AJ; Papadopoulos NE; Liu P; Infante JR; Glass MR; Vaughn CS; LoRusso PM; Cohen RB; Davies MA; Kim KB
Cancer; 2013 Feb; 119(4):799-805. PubMed ID: 22972589
[TBL] [Abstract][Full Text] [Related]
37. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
38. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
39. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
[TBL] [Abstract][Full Text] [Related]
40. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
Lokhandwala PM; Tseng LH; Rodriguez E; Zheng G; Pallavajjalla A; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2019 Jul; 19(1):665. PubMed ID: 31277584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
